ESTIMATION OF THE BENEFIT OF ACETYLSALICYLIC ACID IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES

Download full text PDF
Issue: 
4
Year: 
2015

D. Napalkov, MD I.M. Sechenov First Moscow State Medical University

The paper gives an update on the use of different acetylsalicylic acid formulations (enteric-coated aspirin and buffered aspirin with antacid) for the primary prevention of cardiovascular diseases and on the estimation of the benefit of proposed therapy.
Keywords: 
acetylsalicylic acid
cardiovascular mortality
primary prevention
risk assessment
safety
antacids

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Perk J., DeBacker G., Gohlke H. et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constitutive by representatives of nine societies and by invited experts) // Eur. Heart J. – 2012; 33: 1635–701.
  2. Tanguay J., Bell A., Ackman M., et al. Focused 2012 update of the Canadian Cardiovascular Society Guidelines for the use of antiplatelet therapy // Can. J. Cardiol. – 2013; 29 (11): 1334–45.
  3. Vandvik P., Lincoff A., Gore J. et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th Edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest. – 2012; 141: 637–88.
  4. Kardiovaskuljarnaja profilaktika. Natsional'nye rekomendatsii // Kardiovask. terapija i profilaktika. – 2011; 10 (6, pril. 2).
  5. Hansson L., Zanchetti A., Carruthers S. et al. for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomized trial // Lancet. – 1998; 351: 1755–62.
  6. Zanchetti A., Hansson L., Dahl6. öf B. et al. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk // J. Hypertens. – 2002; 20: 2301–7.
  7. Bulugahapitiya U., Siyambalapitiya S., Sithole J. et al. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis // Diabet. Med. – 2009; 26: 142–8.
  8. Pignone M., Alberts M., Colwell J. et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation // Circulation. – 2010; 121: 2694–701.
  9. Halvorsen S., Andreotti F., Ten Berg J. et al. Aspirin Therapy in Primary Cardiovascular Disease Prevention: A Position paper of the European Society of Cardiology Working Group on Thrombosis // J. Am. Coll. Cardiol. – 2014; 64: 319–27.
  10. Hirata Y., Kataoka H., Shimura T. et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin // Scand. J. Gastroent. – 2011; 46: 803–9
  11. Takada M., Fujimoto M., Hosomi K. Difference in risk of gastrointestinal complications between users of enteric-coated J. Clin. Pharm. Ther. – 2014; 52 (3): 181–91.